S. Jun

发表

Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials.

F. Saad, A. Stopeck, D. Yardley, 2012, European journal of cancer.

RANKL inhibition in the treatment of bone metastases

A. Lipton, S. Jun, 2008, Current opinion in supportive and palliative care.

Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study.

David M. Thomas, J. Blay, M. Roudier, 2010, The Lancet. Oncology.

Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates.

X. Mariette, J. Gralow, J. Body, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Denosumab Induces Tumor Reduction and Bone Formation in Patients with Giant-Cell Tumor of Bone

David M. Thomas, J. Blay, D. Branstetter, 2012, Clinical Cancer Research.

Randomized, active-controlled study of denosumab (AMG 162) in breast cancer patients with bone metastases not previously treated with intravenous (IV) bisphosphonates (BP).

G. Steger, K. Tonkin, A. Lipton, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

An open‐label, phase 2 trial of denosumab in the treatment of relapsed or plateau‐phase multiple myeloma

R. Vij, S. Vadhan-Raj, Y. Qian, 2009, American journal of hematology.

Cancer Therapy : Clinical Denosumab Induces Tumor Reduction and Bone Formation in Patients with Giant-Cell Tumor of Bone

David M. Thomas, J. Blay, D. Branstetter, 2012 .

Denosumab for the treatment of giant cell tumor (GCT) of bone: Final results from a proof-of-concept, phase II study.

J. Blay, M. Roudier, S. Chawla, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Denosumab treatment of giant cell tumor of bone: Interim analysis of an open-label phase II study

David M. Thomas, J. Blay, M. Roudier, 2008 .

Denosumab versus zoledronic acid (ZA) for the treatment of bone metastases: An integrated analysis of results from 2 randomized, double-blind, phase 3 trials

Chunlei Ke, Alison T Stopeck, David H. Henry, 2011 .

Treatment with the Thrombopoietin (TPO)-Receptor Agonist Romiplostim in Thrombocytopenic Patients (Pts) with Low or Intermediate-1 (Int-1) Risk Myelodysplastic Syndrome (MDS): Results of a Randomized, Double-Blind, Placebo(PBO)-Controlled Study

W. Jędrzejczak, G. Mufti, G. Gaidano, 2011 .

A randomized, double-blind study of romiplostim to determine its safety and efficacy in children with immune thrombocytopenia.

Yow-Ming C Wang, J. Bussel, V. Blanchette, 2011, Blood.

Reply to M.S. Aapro

Y. Fujiwara, A. Stopeck, G. Steger, 2011 .

Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study.

Y. Fujiwara, A. Stopeck, M. Lichinitser, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Reply to V. Fusco et al

Y. Fujiwara, A. Stopeck, M. Lichinitser, 2011 .

Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases.

P. Gascón, G. Steger, J. Body, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma.

G. Scagliotti, F. Goldwasser, P. Woll, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

20LBA A double-blind, randomized study of denosumab versus zoledronic acid for the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma

V. Hirsh, D. Henry, S. Vadhan-Raj, 2009 .

Long-Term Efficacy and Safety of Romiplostim Treatment of Adult Patients with Chronic Immune Thrombocytopenia (ITP): Final Report from an Open-Label Extension Study

J. George, J. Bussel, A. Newland, 2010 .

Long‐term treatment with romiplostim in patients with chronic immune thrombocytopenia: safety and efficacy

J. Bussel, J. Viallard, A. Newland, 2013, British journal of haematology.

RANK Ligand Is a Therapeutic Target in Multiple Myeloma

W. Dougall, H. Yeh, S. Jun, 2010 .

Sustained Hemostatic Platelet Counts in Adults with Immune Thrombocytopenia (ITP) Following Cessation of Treatment with the TPO Receptor Agonist Romiplostim: Report of 9 Cases,

J. Bussel, C. Kessler, F. Rodeghiero, 2011 .

An Open-Label, Phase 2 Trial of Denosumab in the Treatment of Relapsed (R) or Plateau-Phase (PP) Multiple Myeloma (MM).

R. Vij, S. Vadhan-Raj, Y. Qian, 2007 .

Extended Efficacy and Safety of Denosumab in Breast Cancer Patients with Bone Metastases Not Receiving Prior Bisphosphonate Therapy

P. Gascón, G. Steger, J. Body, 2008, Clinical Cancer Research.

Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer.

R. Chlebowski, G. Ellis, H. Bone, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Interim Analysis Of Dose-Escalation Stage Of a Phase 1b Study Evaluating Safety and Pharmacology Of GS-9820, a Second-Generation, Selective, PI3Kd-Inhibitor in Recurrent Lymphoid Malignancies

M. Kersten, A. Hagenbeek, A. Kater, 2013 .

2LBA Denosumab versus zoledronic acid for the treatment of breast cancer patients with bone metastases: results of a randomized phase 3 study

Y. Fujiwara, A. Stopeck, G. Steger, 2009 .

Reply to S.M. Sorscher et al

G. Scagliotti, F. Goldwasser, V. Hirsh, 2011 .

A Comparison of Denosumab Versus Zoledronic Acid for the Prevention of Skeletal-Related Events in Breast Cancer Patients with Bone Metastases.

Y. Fujiwara, A. Stopeck, M. Lichinitser, 2009 .

Delaying skeletal-related events in a randomized phase 3 study of denosumab versus zoledronic acid in patients with advanced cancer: an analysis of data from patients with solid tumors

G. Scagliotti, P. Woll, V. Hirsh, 2014, Supportive Care in Cancer.

A randomized trial of denosumab (AMG 162) versus intravenous (IV) bisphosphonates (BP) in cancer patients (pts) with bone metastases (BM) on established IV BP and evidence of elevated bone resorption.

K. Fizazi, A. Lipton, S. Jun, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Incidence of acute phase adverse events following denosumab or intravenous bisphosphonates: results from a randomized, controlled phase II study in patients with breast cancer and bone metastases

A. Lipton, Haijun Ma, S. Jun, 2010 .

Effects of denosumab treatment in breast cancer patients with bone metastases and elevated bone resorption levels after therapy with intravenous bisphosphonates: results of a phase 2 randomized trial.

J. Gralow, K. Fizazi, A. Lipton, 2009 .